Abstract
Epidemiological studies have suggested that obstructive sleep apnea syndrome (OSAS) may increase the risk of developing cognitive impairment. In patients with Alzheimer’s disease (AD), the prevalence of OSAS is much higher than that expected in cognitively healthy subjects. A deeper knowledge of the pathophysiological link between OSAS and AD and the demonstration that OSAS may directly influence the development of cognitive alterations, would increase prevention and treatment strategies for AD patients. In this article, we discuss the evidence of the association between OSAS and dementia. Moreover, we present data about the functional and anatomic cerebral changes induced by OSAS and the possible effects on cognitive activities and on AD pathogenesis. The possibility to positively influence cognitive impairment by OSAS treatment will be also discussed.
Keywords: Alzheimer’s disease, cognitive deterioration, continuous positive airway pressure, obstructive sleep apnea syndrome, pathophysiology, preventive strategies.
CNS & Neurological Disorders - Drug Targets
Title:Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia
Volume: 15 Issue: 6
Author(s): Laura Buratti, Simona Luzzi, Cristina Petrelli, Sara Baldinelli, Giovanna Viticchi, Leandro Provinciali, Claudia Altamura, Fabrizio Vernieri and Mauro Silvestrini
Affiliation:
Keywords: Alzheimer’s disease, cognitive deterioration, continuous positive airway pressure, obstructive sleep apnea syndrome, pathophysiology, preventive strategies.
Abstract: Epidemiological studies have suggested that obstructive sleep apnea syndrome (OSAS) may increase the risk of developing cognitive impairment. In patients with Alzheimer’s disease (AD), the prevalence of OSAS is much higher than that expected in cognitively healthy subjects. A deeper knowledge of the pathophysiological link between OSAS and AD and the demonstration that OSAS may directly influence the development of cognitive alterations, would increase prevention and treatment strategies for AD patients. In this article, we discuss the evidence of the association between OSAS and dementia. Moreover, we present data about the functional and anatomic cerebral changes induced by OSAS and the possible effects on cognitive activities and on AD pathogenesis. The possibility to positively influence cognitive impairment by OSAS treatment will be also discussed.
Export Options
About this article
Cite this article as:
Buratti Laura, Luzzi Simona, Petrelli Cristina, Baldinelli Sara, Viticchi Giovanna, Provinciali Leandro, Altamura Claudia, Vernieri Fabrizio and Silvestrini Mauro, Obstructive Sleep Apnea Syndrome: An Emerging Risk Factor for Dementia, CNS & Neurological Disorders - Drug Targets 2016; 15 (6) . https://dx.doi.org/10.2174/1871527315666160518123930
DOI https://dx.doi.org/10.2174/1871527315666160518123930 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Methamphetamine and HIV Infection, Role in Neurocognitive Dysfunction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chemical Composition and Inhibitory Effects of Hypericum brasiliense and H. connatum on Prolyl Oligopeptidase and Acetylcholinesterase Activities
Medicinal Chemistry Meet Our Editorial Board Member
Recent Patents on CNS Drug Discovery (Discontinued) Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology Pathophysiological Mechanisms Linking Type 2 Diabetes and Dementia: Review of Evidence from Clinical, Translational and Epidemiological Research
Current Diabetes Reviews Brain: The Potential Diagnostic and Therapeutic Target for Glaucoma
CNS & Neurological Disorders - Drug Targets Current Treatment Options for Alzheimer’s Disease and Parkinson’s Disease Dementia
Current Neuropharmacology Dopamine Neurotransmission and Atypical Antipsychotics in Prefrontal Cortex: A Critical Review
Current Topics in Medicinal Chemistry Key Advances in MIP-based Sensors Applied for Cancer and Cardiovascular Biomarkers Detection
Current Topics in Medicinal Chemistry Consciousness, Functional Networks and Delirium Screening
Current Aging Science Proteomic Alterations by Mutations Involved in Parkinson's Disease and Related Disorders
Current Protein & Peptide Science Tau Oligomers as Potential Targets for Immunotherapy for Alzheimers Disease and Tauopathies
Current Alzheimer Research Central Nervous System Agents for Ischemic Stroke: Neuroprotection Mechanisms
Central Nervous System Agents in Medicinal Chemistry Homocysteine: A Risk Factor in Patietns with Cardiovascular Disorders in Pakistan
Current Bioactive Compounds Progranulin Mutations in Ubiquitin-Positive Frontotemporal Dementia Linked to Chromosome 17q21
Current Alzheimer Research Loss of Eyebrows and Eyelashes During Concomitant Treatment with Sitagliptin and Metformin
Current Drug Safety β-Sheet Breakers for Alzheimers Disease Therapy
Current Drug Targets Vascular Damage in Impaired Glucose Tolerance: An Unappreciated Phenomenon?
Current Pharmaceutical Design Anderson-Fabry Disease in Children
Current Pharmaceutical Design Preface: Developments in Understanding of Alzheimer Disease
Current Alzheimer Research